Efzofitimod for COVID-19: real-time analysis

Download Image

Post

c19early.org

Efzofitimod for COVID-19

1 study with 32 patients

Serious outcome risk

Efzofitimod

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Efzofitimod studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−291%

Mortality (1)−291%

Hospitalization (1)−24%

RCTs (1)−291%

Late (1)−291%

00.511.5+

← Efzofitimod
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Efzofitimod is an intravenously administered Fc-fusion biologic immunomodulator that binds neuropilin-2 to down-regulate inflammatory responses.


Oct 23 2020	Walker et al., NCT04412668	A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
Oct 23 2020	291% higher mortality (p=1), 24% longer hospitalization (p=0.53), and 11% worse recovery (p=1). RCT 32 hospitalized COVID-19 patients showing no significant differences with efzofitimod.